Hematopoietic Stem Cell Transplantation - Market Insight, Epidemiology And Market Forecast - 2032

Hematopoietic Stem Cell Transplantation - Market Insight, Epidemiology And Market Forecast - 2032

DelveInsight’s ‘Hematopoietic Stem Cell Transplantation (HSCT) - Market Insights, Epidemiology, and Market Forecast–2032’ report delivers an in-depth understanding of HSCT historical and forecasted epidemiology as well as the HSCT market trends in the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The HSCT market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM HSCT market size. The report also covers HSCT procedure, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

• The United States
• EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019–2032

Hematopoietic Stem Cell Transplantation (HSCT) Understanding

Hematopoietic Stem Cell Transplantation (HSCT) Overview

Hematopoietic stem cell transplantation (HSCT) administers healthy hematopoietic stem cells (HSC) to patients with defective or depleted bone marrow. This improves bone marrow function and, depending on the disease being treated, leads to either the destruction of malignant tumor cells or the generation of functional cells that can replace the dysfunctional ones, as in the case of immune-deficiency syndromes, hemoglobinopathies, and other diseases. HSCs are immature blood cells found in the peripheral blood and the bone marrow. These are also called blood stem cells. These are produced in the bone marrow and can develop into any type of blood cell required by the body. Stem cells divide and mature, replacing older and worn-out blood cells.

Continued in the report…

Hematopoietic Stem Cell Transplantation (HSCT) Procedure

The procedure of HSCT includes donor matching, mobilization, harvesting, conditioning, and infusion. The selection of a donor is an essential factor in the success of hematopoietic cell transplantation. There are many possible choices for an allogeneic HSC donor, which are as follows:

• Matched donor - A donor with a comparable genetic makeup to the patient is preferable to assist or limit the issues that the expected immunological reaction might create. Siblings are usually the only members of the family. They may be matched entirely at the critical genes known as the human leukocyte antigen or HLA genes, which are proteins located on cellular surfaces.
• Matched unrelated donor - If no siblings are available, testing their blood does not indicate a match, or sibling donors are deemed unsuitable, a matched unrelated donor may be utilized. The search for a suitable donor can be carried out utilizing transplant registries worldwide.

Continued in the report…

Hematopoietic Stem Cell Transplantation (HSCT) Indications

Indications for HSCT have been bifurcated into malignant and nonmalignant diseases.

 Malignant disease

• Multiple Myeloma - Studies have shown increased overall survival and progression-free survival in patients younger than 65 when consolidation therapy with melphalan is initiated, followed by ASCT and lenalidomide maintenance therapy. The study showed a favorable outcome of high-dose melphalan plus stem-cell transplantation compared with consolidation therapy with melphalan, prednisone, and lenalidomide (MPR). It also showed a better outcome in patients who received maintenance therapy with lenalidomide.
• Hodgkin and Non-Hodgkin Lymphoma - Studies have shown that chemotherapy followed by ASCT in cases of recurrent lymphomas (HL and NHL) that do not respond to conventional chemotherapy has better outcomes. A randomized controlled trial by Schmitz et al. showed a better 3-year outcome of high-dose chemotherapy with ASCT compared to aggressive conventional chemotherapy in relapsed chemo sensitive Hodgkin lymphoma. However, the overall survival was not significantly different between the two groups. The number of hematopoietic SCT recipients comes second after multiple myeloma, according to CIBMTR.

Continued in the report…..

Hematopoietic Stem Cell Transplantation (HSCT) Epidemiology

The epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Cases of Hematopoietic Stem Cell Transplantation, Type-specific Cases of Hematopoietic Stem Cell Transplantation, and Total Cases of Hematopoietic Stem Cell Transplantation by Indication scenario in the 7MM covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Key Findings

• In 2021, the total cases of HSCT in the 7MM countries were 55,999, and these cases are anticipated to increase during the study period. The US accounted for 23,971 cases of HSCT in 2021.
• Among the European countries, Germany had the highest number of cases of HSCT in 2021, i.e., 7,085 cases, followed by Italy which had 5,625 cases in 2021. On the other hand, Spain had the lowest number of cases of HSCT, i.e. 3,439 cases in 2021.
• In terms of type-specific cases of HSCT, the percentage of autologous HSCT cases is more in comparison to allogeneic HSCT across the 7MM except for Japan.
• Japan, in 2021, accounted for 5,872 cases of HSCT, which is expected to increase during the study period.
• In terms of indications for HSCT, multiple myeloma/plasma cell disorders bags the largest pool among all the considered indications in the 7MM except for Japan

Hematopoietic Stem Cell Transplantation (HSCT) Drug Chapters

Hematopoietic Stem Cell Transplantation Emerging Drugs

Iomab-B (CD45): Actinium Pharmaceuticals

Iomab-B, via the monoclonal antibody apamistamab, targets CD45, an antigen widely expressed on all types of blood cancer cells and immune cells, including bone marrow progenitor stems cells. Iomab-B links apamistamab to the radioisotope iodine-131 and, once attached to its target cells, emits energy that travels a relatively long distance, destroying a patient’s cancer cells and ablating their bone marrow. By carrying iodine-131 directly to the bone marrow in a targeted manner, Actinium believes Iomab-B will avoid side effects of non-targeted chemotherapy and/or external beam radiation on most healthy tissues while effectively killing the patient's cancer and marrow cells.

Product details in the report…

Treosulfan: Medexus Pharmaceuticals /medac Pharma

Treosulfan is part of a preparative regimen for allo-HSCT to be used in combination with fludarabine, used in treating eligible patients with acute myeloid leukemia and myelodysplastic syndromes. Treosulfan is a prodrug of a bifunctional alkylating agent with cytotoxic activity to hematopoietic precursor cells. The activity of treosulfan is due to the spontaneous conversion into a mono-epoxide intermediate and L-diepoxybutan. The epoxides formed alkylate nucleophilic centers of deoxyribonucleic acid (DNA) and induced DNA cross-links, which are responsible for the stem cell depleting and antineoplastic effects.

Products detail in the report…

Motixafortide (BL-8040): BioLineRX

Motixafortide (formerly known as BL-8040/BKT140) is a novel selective inhibitor of the CXCR4 chemokine receptor. CXCR4 is a well-validated therapeutic target involved in the mobilization and trafficking of hematopoietic stem cells, immune cells, and cancer cells from the bone marrow and the lymph nodes to the peripheral blood. Motixafortide is being developed as a platform for several indications, including mobilization of hematopoietic stem cells (HSCs) for autologous transplantations, treatment of solid tumors, and other hematological malignancies.

Product details in the report…

Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook

Hematopoietic stem cell transplantation using hematopoietic progenitor cells from the patient (autologous HSCT) or a donor (allogeneic HSCT) is a potentially curative therapy for many life-threatening cancers and non-malignant disorders.

Transplantation of hematopoietic stem cells (HSCT) has become the standard of care for many patients with defined congenital or acquired disorders of the hematopoietic system or with chemo- radio- or immuno- sensitive malignancies. Over the last two decades, HSCT has seen rapid expansion and a constant evolution in technology use. Multiple myeloma and non-Hodgkin's lymphoma remain the most common indications for high-dose chemotherapy and autologous peripheral blood stem cell rescue.

Hematopoietic stem cell transplantation (HSCT) can be curative for hematologic malignancies. As a result of receiving preparative treatments for HSCT (“conditioning”) involving high-dose chemotherapy with/without total body irradiation (TBI), patients become profoundly immunocompromised and prone to opportunistic infections while awaiting donor immune reconstitution. These infectious risks and other complications including graft rejection, graft-versus-host disease (GVHD), and disease relapse, have been the main obstacles to HSCT success.

Continued in the report…..

Key Findings

• The market size of HSCT in the 7MM was observed to be USD 763 million in 2021.
• In 2021, the US has the largest HSCT market size of USD 491 million among the 7MM countries.
• Among the EU-5 countries, Germany had the highest market size for HSCT in 2021, i.e., USD 62 million. The lowest market size was estimated in Spain with USD 30 million in 2021.
• In Japan, the market size for HSCT was observed to be USD 47 million in 2021.

The United States Market Outlook

This section provides the total HSCT market size and market size by therapies in the United States.

EU-5 Market Outlook

The total HSCT market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total HSCT market size and market size by therapies in Japan are provided.

Hematopoietic Stem Cell Transplantation (HSCT) Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the HSCT market or expected to get launched in the market during the study period 2019–2032. The analysis covers the HSCT market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, and reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Hematopoietic Stem Cell Transplantation (HSCT) Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers detailed information on collaborations, acquisitions, merger, licensing, and patent details for HSCT emerging therapies.

Reimbursement Scenario in Hematopoietic Stem Cell Transplantation (HSCT)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitive market Intelligence analysis of the HSCT market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers a descriptive overview of HSCT, explaining its procedure, types, indications, and currently available therapies.
• Comprehensive insight has been provided into HSCT epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for HSCT is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of the HSCT market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM HSCT market.

Report Highlights

• The robust pipeline with novel MOA and oral ROA, increasing prevalence, and effectiveness of drugs will positively drive the HSCT market.
• The companies and academics are working to assess challenges and seek opportunities that could influence HSCT R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition using HSCT.
• Major players are involved in developing therapies for HSCT. The launch of emerging therapies will significantly impact the HSCT market.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Hematopoietic Stem Cell Transplantation (HSCT) Report Insights

• Patient Population
• Therapeutic Approaches
• HSCT Pipeline Analysis
• HSCT Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Hematopoietic Stem Cell Transplantation (HSCT) Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• HSCT Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Hematopoietic Stem Cell Transplantation (HSCT) Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• SWOT analysis

Key Questions

Market Insights:

• What was the HSCT market share (%) distribution in 2019 and how it would look like in 2032?
• What would be the HSCT total market size as well as market size by therapies across the 7MM during the forecast period (2022–2032)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest HSCT market size during the forecast period (2022–2032)?
• At what CAGR, the HSCT market is expected to grow at the 7MM level during the forecast period (2022–2032)?
• What would be the HSCT market outlook across the 7MM during the forecast period (2022–2032)?
• What would be the HSCT market growth till 2032 and what will be the resultant market size in the year 2032?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the risk, burdens, and unmet needs of HSCT?
• What is the historical HSCT patient pool in the United States, EU-5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of HSCT at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to HSCT?
• Out of the above-mentioned countries, which country would have the highest cases of HSCT during the forecast period (2022–2032)?
• At what CAGR are these cases expected to grow across the 7MM during the forecast period (2022–2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current treatment practices in HSCT along with the approved therapy?
• What are the current treatment guidelines for HSCT?
• What are the HSCT marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
• How many companies are developing therapies for HSCT?
• How many emerging therapies are in the mid-stage and late stages of development for HSCT?
• What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the HSCT therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for HSCT and their status?
• What are the key designations that have been granted for the emerging therapies for HSCT?
• What are the 7MM historical and forecasted market of HSCT?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving HSCT.
• To understand the future market competition in the HSCT market and an insightful review of the market.
• Organize sales and marketing efforts by identifying the best opportunities for HSCT in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the HSCT market.
• To understand the future market competition in the HSCT market.